Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium

Ana Babic, Daniel W. Cramer, Linda E. Kelemen, Martin Köbel, Helen Steed, Penelope M. Webb, Sharon E. Johnatty, Anna DeFazio, Diether Lambrechts, Marc T. Goodman, Florian Heitz, Keitaro Matsuo, Satoyo Hosono, Beth Y. Karlan, Allan Jensen, Susanne K. Kjær, Ellen L Goode, Tanja Pejovic, Melissa Moffitt, Estrid HøgdallClaus Høgdall, Iain McNeish, Kathryn L. Terry

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals. Methods: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels. Results: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2 was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels. Conclusion: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalCancer Causes and Control
DOIs
StateAccepted/In press - Jan 3 2017

Fingerprint

Ovarian Neoplasms
Antigens
Neoplasms
Epidemiologic Factors
Body Mass Index
Tubal Sterilization
Reproductive History
Endometriosis
Oral Contraceptives
Parity

Keywords

  • Biomarker
  • CA125
  • Ovarian cancer
  • Predictors
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Predictors of pretreatment CA125 at ovarian cancer diagnosis : a pooled analysis in the Ovarian Cancer Association Consortium. / Babic, Ana; Cramer, Daniel W.; Kelemen, Linda E.; Köbel, Martin; Steed, Helen; Webb, Penelope M.; Johnatty, Sharon E.; DeFazio, Anna; Lambrechts, Diether; Goodman, Marc T.; Heitz, Florian; Matsuo, Keitaro; Hosono, Satoyo; Karlan, Beth Y.; Jensen, Allan; Kjær, Susanne K.; Goode, Ellen L; Pejovic, Tanja; Moffitt, Melissa; Høgdall, Estrid; Høgdall, Claus; McNeish, Iain; Terry, Kathryn L.

In: Cancer Causes and Control, 03.01.2017, p. 1-10.

Research output: Contribution to journalArticle

Babic, A, Cramer, DW, Kelemen, LE, Köbel, M, Steed, H, Webb, PM, Johnatty, SE, DeFazio, A, Lambrechts, D, Goodman, MT, Heitz, F, Matsuo, K, Hosono, S, Karlan, BY, Jensen, A, Kjær, SK, Goode, EL, Pejovic, T, Moffitt, M, Høgdall, E, Høgdall, C, McNeish, I & Terry, KL 2017, 'Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium', Cancer Causes and Control, pp. 1-10. https://doi.org/10.1007/s10552-016-0841-3
Babic, Ana ; Cramer, Daniel W. ; Kelemen, Linda E. ; Köbel, Martin ; Steed, Helen ; Webb, Penelope M. ; Johnatty, Sharon E. ; DeFazio, Anna ; Lambrechts, Diether ; Goodman, Marc T. ; Heitz, Florian ; Matsuo, Keitaro ; Hosono, Satoyo ; Karlan, Beth Y. ; Jensen, Allan ; Kjær, Susanne K. ; Goode, Ellen L ; Pejovic, Tanja ; Moffitt, Melissa ; Høgdall, Estrid ; Høgdall, Claus ; McNeish, Iain ; Terry, Kathryn L. / Predictors of pretreatment CA125 at ovarian cancer diagnosis : a pooled analysis in the Ovarian Cancer Association Consortium. In: Cancer Causes and Control. 2017 ; pp. 1-10.
@article{c0c6802333ca43d89832b930c81b39f4,
title = "Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium",
abstract = "Purpose: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals. Methods: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels. Results: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2 was associated with 10{\%} (95{\%} CI 2, 19{\%}) higher CA125 levels, while race (non-white vs. white) was associated with 15{\%} (95{\%} CI 4, 27{\%}) higher CA125 levels. Conclusion: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.",
keywords = "Biomarker, CA125, Ovarian cancer, Predictors, Prognosis",
author = "Ana Babic and Cramer, {Daniel W.} and Kelemen, {Linda E.} and Martin K{\"o}bel and Helen Steed and Webb, {Penelope M.} and Johnatty, {Sharon E.} and Anna DeFazio and Diether Lambrechts and Goodman, {Marc T.} and Florian Heitz and Keitaro Matsuo and Satoyo Hosono and Karlan, {Beth Y.} and Allan Jensen and Kj{\ae}r, {Susanne K.} and Goode, {Ellen L} and Tanja Pejovic and Melissa Moffitt and Estrid H{\o}gdall and Claus H{\o}gdall and Iain McNeish and Terry, {Kathryn L.}",
year = "2017",
month = "1",
day = "3",
doi = "10.1007/s10552-016-0841-3",
language = "English (US)",
pages = "1--10",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Predictors of pretreatment CA125 at ovarian cancer diagnosis

T2 - a pooled analysis in the Ovarian Cancer Association Consortium

AU - Babic, Ana

AU - Cramer, Daniel W.

AU - Kelemen, Linda E.

AU - Köbel, Martin

AU - Steed, Helen

AU - Webb, Penelope M.

AU - Johnatty, Sharon E.

AU - DeFazio, Anna

AU - Lambrechts, Diether

AU - Goodman, Marc T.

AU - Heitz, Florian

AU - Matsuo, Keitaro

AU - Hosono, Satoyo

AU - Karlan, Beth Y.

AU - Jensen, Allan

AU - Kjær, Susanne K.

AU - Goode, Ellen L

AU - Pejovic, Tanja

AU - Moffitt, Melissa

AU - Høgdall, Estrid

AU - Høgdall, Claus

AU - McNeish, Iain

AU - Terry, Kathryn L.

PY - 2017/1/3

Y1 - 2017/1/3

N2 - Purpose: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals. Methods: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels. Results: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2 was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels. Conclusion: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

AB - Purpose: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian cancer patients, to monitor response to treatment and detect cancer recurrence. Besides tumor characteristics, CA125 levels are also influenced by several epidemiologic factors, such as age, parity, and oral contraceptive use. Identifying factors that influence CA125 levels in ovarian cancer patients could aid in the interpretation of CA125 values for individuals. Methods: We evaluated predictors of pretreatment CA125 in 13 studies participating in the Ovarian Cancer Association Consortium. This analysis included a total of 5,091 women with invasive epithelial ovarian cancer with pretreatment CA125 measurements. We used probit scores to account for variability in CA125 between studies and linear regression to estimate the association between epidemiologic factors and tumor characteristics and pretreatment CA125 levels. Results: In age-adjusted models, older age, history of pregnancy, history of tubal ligation, family history of breast cancer, and family history of ovarian cancer were associated with higher CA125 levels while endometriosis was associated with lower CA125 levels. After adjusting for tumor-related characteristics (stage, histology, grade), body mass index (BMI) higher than 30 kg/m2 was associated with 10% (95% CI 2, 19%) higher CA125 levels, while race (non-white vs. white) was associated with 15% (95% CI 4, 27%) higher CA125 levels. Conclusion: Our results suggest that high BMI and race may influence CA125 levels independent of tumor characteristics. Validation is needed in studies that use a single assay for CA125 measurement and have a diverse study population.

KW - Biomarker

KW - CA125

KW - Ovarian cancer

KW - Predictors

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85008168585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008168585&partnerID=8YFLogxK

U2 - 10.1007/s10552-016-0841-3

DO - 10.1007/s10552-016-0841-3

M3 - Article

C2 - 28050675

AN - SCOPUS:85008168585

SP - 1

EP - 10

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

ER -